Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.
Jonathan D TwardLauren LenzAlexander GutinWyatt CleggChelsea R KastenRobert FinchTodd CohenJeff M MichalskiAmar U KishanPublished in: JCO precision oncology (2024)
The precise and personalized risk estimate of metastasis provided by the CCR score can help inform patients and physicians when considering treatment intensification.
Keyphrases
- newly diagnosed
- cell cycle
- prostate cancer
- radiation therapy
- end stage renal disease
- cell proliferation
- chronic kidney disease
- primary care
- radical prostatectomy
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- dendritic cells
- stem cells
- immune response
- regulatory t cells
- patient reported outcomes
- locally advanced
- rectal cancer
- smoking cessation